130 related articles for article (PubMed ID: 35810485)
1. Apoptosis is responsible for the cytotoxic effects of anti-GD2 ganglioside antibodies and aurora A kinase inhibitors on human neuroblastoma cells.
Durbas M; Rokita H; Horwacik I; Wiśniewska A; Nowak I
Acta Biochim Pol; 2022 Jul; 69(3):485-494. PubMed ID: 35810485
[TBL] [Abstract][Full Text] [Related]
2. GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells.
Durbas M; Pabisz P; Wawak K; Wiśniewska A; Boratyn E; Nowak I; Horwacik I; Woźnicka O; Rokita H
Apoptosis; 2018 Oct; 23(9-10):492-511. PubMed ID: 30027525
[TBL] [Abstract][Full Text] [Related]
3. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.
Horwacik I; Durbas M; Boratyn E; Węgrzyn P; Rokita H
Cancer Lett; 2013 Dec; 341(2):248-64. PubMed ID: 23962557
[TBL] [Abstract][Full Text] [Related]
4. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.
Horwacik I; Rokita H
Int J Oncol; 2017 May; 50(5):1899-1914. PubMed ID: 28393238
[TBL] [Abstract][Full Text] [Related]
5. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
6. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of the PHLDA1 gene in IMR-32 neuroblastoma cells increases levels of Aurora A, TRKB and affects proteins involved in apoptosis and autophagy pathways.
Durbas M; Horwacik I; Boratyn E; Rokita H
Int J Oncol; 2016 Aug; 49(2):823-37. PubMed ID: 27278006
[TBL] [Abstract][Full Text] [Related]
8. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.
Siebert N; Seidel D; Eger C; Jüttner M; Lode HN
PLoS One; 2014; 9(9):e107692. PubMed ID: 25226154
[TBL] [Abstract][Full Text] [Related]
9. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
[TBL] [Abstract][Full Text] [Related]
10. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
[TBL] [Abstract][Full Text] [Related]
11. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
12. Analysis of genes involved in response to doxorubicin and a GD2 ganglioside-specific 14G2a monoclonal antibody in IMR-32 human neuroblastoma cells.
Horwacik I; Durbas M; Boratyn E; Sawicka A; Węgrzyn P; Krzanik S; Górka A; Drożniak J; Augustyniak E; Kowalczyk A; Rokita H
Acta Biochim Pol; 2015; 62(3):423-33. PubMed ID: 26284262
[TBL] [Abstract][Full Text] [Related]
13. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
14. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
[TBL] [Abstract][Full Text] [Related]
15. Anti-ganglioside GD2 monoclonal antibody synergizes with cisplatin to induce endoplasmic reticulum-associated apoptosis in osteosarcoma cells.
Zhu W; Mao X; Wang W; Chen Y; Li D; Li H; Dou P
Pharmazie; 2018 Feb; 73(2):80-86. PubMed ID: 29442009
[TBL] [Abstract][Full Text] [Related]
16. Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells.
Liu B; Wu Y; Zhou Y; Peng D
PLoS One; 2014; 9(4):e93576. PubMed ID: 24727660
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.
Kalinovsky DV; Kibardin AV; Kholodenko IV; Svirshchevskaya EV; Doronin II; Konovalova MV; Grechikhina MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764367
[TBL] [Abstract][Full Text] [Related]
18. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
[TBL] [Abstract][Full Text] [Related]
19. [Caspases participarion in the cell death induced by GD2-specific monoclonal antibody].
Vishniakova PA; Doronin II; Holodenko IV; Riazantsev DIu; Molotkovskaia IM; Holodenko RV
Bioorg Khim; 2014; 40(3):305-14. PubMed ID: 25898737
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.
Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S
PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]